// App-Quantinova.ai

1151-231 : IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL

Researchers

Presenter

  • Kurt Huber

Principal Investigators

  • Christian W. Hamm

  • Arnoud va-t Hof

  • Vojko Kanic

  • Frederic Lapostolle

  • Pierre Coste

  • Michel Thicoipe

  • Giovanni Gordini

  • Jacob Steinmetz

  • Freek Verheugt

  • Jennifer Adgey

  • Lutz Nibbe

Medical Centers

  • Hopital Bichat, Assistance Publique des Hopitaux de Paris, Paris, France

  • Philippe Gabriel Steg, Wilhelminenspital, Vienna, Austria

Locations

  • France

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Venous thrombosis

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • Aryl hydrocarbon receptor nuclear translocator-like protein 1

Drug/Treatment

  • Clopidogrel bisulfate

  • Ticagrelor

  • Prasugrel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved